Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HK2 | P52789 | 5/20 | 0.45 |
| ▸ | HK1 | P19367 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | PYGB | P11216 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Streptozosin SCHEMBL18402590 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL4748 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL13840968 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL17327962 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL15012795 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10201155 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL17328035 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL10262780 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL18402588 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| Streptozosin SCHEMBL444088 | 1.00 | LMNA (1.00) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5691307-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-25 | — | — | US | claimed |
| EP-4681778-A2 | COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS | Orega Biotech (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-3946377-B1 | COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS | OREGA BIOTECH (FR) | 2025-12-10 | — | — | EP | disclosed |
| US-20230045494-A1 | COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-09 | — | — | US | disclosed |
| EP-4110810-A1 | COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS | Orega Biotech (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-20220281967-A1 | NOVEL IL-17B ANTIBODIES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-09-08 | — | — | US | disclosed |
| US-20220175815-A1 | COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-06-09 | — | — | US | disclosed |
| EP-4007775-A1 | NOVEL IL-17B ANTIBODIES | Orega Biotech (FR) | 2022-06-08 | — | — | EP | disclosed |
| EP-3946377-A1 | COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS | Orega Biotech (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-10953042-B2 | Vanadium insulin-mimetics, methods of preparation, and methods for treatment of diabetes | THE UNIVERSITY OF TRINIDAD AND TOBAGO (TT) | 2021-03-23 | — | — | US | disclosed |
| US-6060458-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS; GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-09 | — | — | US | disclosed |
| US-5958932-A | ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999041269-A1 | OLIGODEOXYRIBONUCLEOTIDES COMPRISING O6-BENZYLGUANINE AND THEIR USE | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-08-19 | — | — | WO | disclosed |
| US-5916894-A | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-06-29 | — | — | US | disclosed |
| US-5753668-A | Substituted benzyloxypyrimidines and their inactivation of O6 -alkylguanine-DNA alkyltransferase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | disclosed |
| US-5525606-A | CHEMOTHERAPEUTIC ANTITUMOR AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1996004281-A1 | SUBSTITUTED O6-BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-02-15 | — | — | WO | disclosed |
| US-4360663-A | Steroid hormone-antitumor derivatives | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-11-23 | — | — | US | disclosed |
| US-4260736-A | NAPHTHACENE HEXAPYRANOSIDE DERIVATIVE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953042-B2 | Vanadium insulin-mimetics, methods of preparation, and methods for treatment of diabetes | IAPP, INSR, GPR119 | LMNA 4074/4885KDM4E 3089/4885CYP2D6 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.